Printer Friendly
The Free Library
22,741,889 articles and books

IDEC Pharmaceuticals Reports Second Quarter 2001 Results; Rituxan Sales Increase 86% Over 2Q 2000 and Earnings Increase to $0.15 Per Share.



Business Editors & Health/Medical Writers

BIOWIRE2K

SAN DIEGO--(BW HealthWire)--July 19, 2001

IDEC IDEC Instituto Brasileiro de Defesa do Consumidor (Portugese: Brazilian Consumer Protection Agency)
IDEC Information Design & End-User Computing
IDEC Interior Design Educators Council, Inc.
 Pharmaceuticals Corporation (Nasdaq: IDPH IDPH Illinois Department of Public Health
IDPH Iowa Department of Public Health
) today announced its financial results for the second quarter ended June 30, 2001. Total revenues for the second quarter ended June 30, 2001 were $64.8 million compared to $39.0 million for the second quarter of 2000. Net income was $25.2 million, or $0.15 per share on a diluted di·lute  
tr.v. di·lut·ed, di·lut·ing, di·lutes
1. To make thinner or less concentrated by adding a liquid such as water.

2. To lessen the force, strength, purity, or brilliance of, especially by admixture.
 basis, compared to $14.7 million, or $0.09 per share on a diluted basis, for the same period in 2000. As discussed in our release for the year ended December 31, 2000, we adopted the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 101 in the fourth quarter of fiscal 2000 effective as of January 1, 2000, which resulted in the restatement Restatement

A revision in a company's earlier financial statements.

Notes:
The need for restating financial figures can result from fraud, misrepresentation, or a simple clerical error.
 of the financial results for the three and six months ended June 30, 2000.

Revenues for the second quarter of 2001 included $58.1 million recorded for IDEC's joint business arrangement with Genentech, Inc. for the commercialization of Rituxan(R) (Rituximab) compared to $31.3 million for the first quarter of 2000. All per share amounts for the three and six months ended June 30, 2000 have been restated to reflect IDEC's three-for-one stock split in January 2001.

Rituxan Revenues

Rituxan is copromoted in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  by IDEC and Genentech. U.S. net sales Net Sales

The amount a seller receives from the buyer after costs associated with the sale are deducted.

Notes:
This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight
 of Rituxan, as recorded by Genentech, in the second quarter of 2001 were $180.0 million compared to $96.7 million for the same period in 2000.

"We are very gratified grat·i·fy  
tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies
1. To please or satisfy: His achievement gratified his father. See Synonyms at please.

2.
 with Rituxan's robust growth, especially when you step back and look at its year-to-year progress -- an 86 percent rise in the second quarter of this year compared to the same period last year," said William H. Rastetter, IDEC's chief executive officer. "This growth is driven, in part, by the expanded package insert package insert Pharmacology A synopsis of key physicochemical, pharmacologic, clinical efficacy, and clinical safety properties of a prescription drug, bundled therewith, intended to be highly readable and helpful to clinicians looking for specific  approved early in the quarter, which has stimulated our discussions on the utility of Rituxan with medical oncologists medical oncologist  Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists. ."

Revenues from unconsolidated joint business reflect the financial results from the U.S. marketing of Rituxan by IDEC and Genentech. Revenues from unconsolidated joint business for 2001 consist of IDEC's share of pretax pre·tax  
adj.
Existing before tax deductions: pretax income.

pretax adj [profit] → vor (Abzug der) Steuern 
 copromotion profits, reimbursements from Genentech for IDEC's Rituxan-related sales force and development expenses and royalty income from F. Hoffmann-La Roche Ltd. on the sales of Rituxan outside the United States.

IDEC's share of pretax copromotion profits consists of two tiers, a lower tier that resets annually at the beginning of each year and a higher tier, which applies once an annual fixed pretax copromotion profit level is met. IDEC began recording its share of pretax copromotion profits at the higher tier during the first quarter of 2001 compared to the beginning of the second quarter in 2000.

Operating Costs operating costs nplgastos mpl operacionales  and Expenses

Operating costs and expenses for the second quarter of 2001 increased to $33.1 million from $23.6 million for the second quarter of 2000. Year-to-date operating costs and expenses increased by $19.7 million to $66.3 million in 2001, compared to $46.6 million in 2000. The higher 2001 operating expenses Operating expenses

The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted.
 are primarily the result of increased clinical testing for our various products under development, sales and marketing expenses, personnel expenses and facility expenses.

IDEC ended the second quarter of 2001 with $821.5 million in cash, cash equivalents and marketable securities Marketable Securities

Very liquid securities that can be converted into cash quickly at a reasonable price.

Notes:
Marketable securities are very liquid as they tend to have maturities less than one year, and the rate at which these securities can be bought or sold has
, compared to $750.5 million at December 31, 2000. Increases in cash stem primarily from operations and stock purchases under employee stock plans.

FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 Approved sBLA for Rituxan

On May 14, 2001, IDEC and Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) for Rituxan.

The new product labeling includes retreatment with Rituxan after a prior course of Rituxan therapy, initial treatment with eight weekly infusions of Rituxan, compared to four infusions, and treatment of bulky disease bulky disease Oncology A term for a CA with a considerable tumor burden–'bulk'; BD generally has a poorer prognosis independent of the histologic grade; a major priority in oncology is to debulk a tumor to optimize chemo- or RT. See Debulking operation.  (tumors greater than 10 centimeters) for patients with relapsed or refractory refractory

Material that is not deformed or damaged by high temperatures, used to make crucibles, incinerators, insulation, and furnaces, particularly metallurgical furnaces.
, low-grade or follicular fol·lic·u·lar
adj.
1. Relating to, having, or resembling a follicle or follicles.

2. Affecting or growing out of a follicle or follicles.
, CD20 positive B-cell non-Hodgkin's lymphoma non-Hodg·kin's lymphoma
n.
Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells.


Non-Hodgkin's lymphoma 
 (NHL NHL Non-Hodgkin's lymphoma, see there ). Additionally, the two companies have emphasized already existing safety information in the revised package insert for physicians concerning rare severe and potentially fatal mucocutaneous mucocutaneous /mu·co·cu·ta·ne·ous/ (-ku-ta´ne-us) pertaining to or affecting the mucous membrane and the skin.

mu·co·cu·ta·ne·ous
adj.
Of or relating to the skin and a mucous membrane.
 skin reactions that have occurred in patients who have received Rituxan.

Rituxan Approved in Japan

On June 20, 2001, Rituxan was approved by the Japanese health authorities for the treatment of certain B-cell non-Hodgkin's lymphoma (NHL). Rituxan will be co-promoted by Nippon Roche and Zenyaku Kogyo in Japan, where there are approximately 13,000 NHL patients.

General Information

Rituxan was discovered by IDEC and is jointly developed by IDEC, Genentech Inc., F. Hoffmann-La Roche Ltd. of Switzerland and Zenyaku Kogyo Co. Ltd. of Japan. Hoffmann-La Roche Ltd. has marketing rights to Rituximab outside of the United States and Japan.

IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for the treatment of cancer and autoimmune diseases Autoimmune diseases
A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs.

Mentioned in: Complement Deficiencies, Premature Menopause
. IDEC's antibody products act chiefly through immune system immune system

Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders.
 mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient's blood or lymphatic system lymphatic system (lĭmfăt`ĭk), network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. .

For a menu of IDEC's current news releases and quarterly reports or to retrieve a specific release, call (888) 329-2309. On the Internet check the News Center at IDEC's website: http://www.idecpharm.com. As previously announced, interested parties can access a live webcast of management's discussion of the second quarter 2001 results and a regulatory update on ZEVALIN(TM) through a link at IDEC's website at http://www.idecpharm.com. The webcast will begin today at 1:30 p.m. Pacific Standard Time and will remain available for 48 hours.

The statements made in this press release contain certain forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 that involve a number of risks and uncertainties. Actual events or results may differ from IDEC's expectations. For example, the timing, success and cost of preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable.

pre·clin·i·cal
adj.
1.
 research and clinical studies, the timing, acceptability and review periods for regulatory filings, the timing of and ability to obtain regulatory approval of products, the achievement of future product sales, the level of manufacturing performance and the risk factors listed from time to time in IDEC's SEC filings including but not limited to its Annual Report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.


Form 10-K

See 10-K.
 for the year ended December 31, 2000 and Form 10-Q Form 10-Q

See 10-Q.
 for the quarter ended March 31, 2001, may affect the actual results achieved by IDEC. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

IDEC Pharmaceuticals and Rituxan are registered U.S. trademarks of the company. ZEVALIN is a trademark of the company. The company's headquarters are located at 3030 Callan Road, San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA 92121.

IDEC Pharmaceuticals' press releases are available at no charge through Business Wire's News on Demand Plus. For a menu of IDEC's current press releases and quarterly reports or to retrieve a specific release, call 888/329-2309. On the Internet, check the News Center at IDEC's website: http://www.idecpharm.com.


IDEC PHARMACEUTICALS CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

                         Three months            Six months
                         ended June 30,         ended June 30,
                      --------------------  --------------------
                        2001      2000(2)      2001      2000(2)
                      ---------  ---------  ---------  ---------
Revenues:
 Revenues from
  unconsolidated
  joint business      $  58,072  $  31,302  $ 106,630  $  53,195
 Contract revenues        2,152      6,088      3,507      9,592
 License fees             4,625      1,625     11,250      3,250
                      ---------  ---------  ---------  ---------
 Total revenues          64,849     39,015    121,387     66,037
Operating costs and
 expenses:
  Manufacturing costs      --         --         --        2,134
  Research and
   development           21,691     17,038     43,161     31,760
  Selling, general
   and administrative    11,430      6,600     23,134     12,677
                      ---------  ---------  ---------  ---------
                         33,121     23,638     66,295     46,571
                      ---------  ---------  ---------  ---------
Income from
 operations              31,728     15,377     55,092     19,466
Interest income, net      8,257      2,389     17,980      4,265
                      ---------  ---------  ---------  ---------
Income before income
 tax provision           39,985     17,766     73,072     23,731
Income tax provision    (14,832)    (3,091)   (27,112)    (4,109)
                      ---------  ---------  ---------  ---------
Income before
 cumulative effect of
 accounting change       25,153     14,675     45,960     19,622
Cumulative effect of
 accounting change,
 net of income tax
 benefit of $487           --         --         --       (9,263)
                      ---------  ---------  ---------  ---------
Net income            $  25,153  $  14,675  $  45,960  $  10,359
                      =========  =========  =========  =========

Basic earnings per
  share (1):
 Before cumulative
  effect of
  accounting change   $    0.17  $    0.11  $    0.31  $    0.15
 Cumulative effect of
  accounting change        --         --         --        (0.07)
                      ---------  ---------  ---------  ---------
Basic earnings per
 share                $    0.17  $    0.11  $    0.31  $    0.08

Diluted earnings per
  share (1):
 Before cumulative
  effect of
  accounting change   $    0.15  $    0.09  $    0.27  $    0.13
 Cumulative effect of
  accounting change        --         --         --        (0.06)
                      ---------  ---------  ---------  ---------
Diluted earnings per
 share                $    0.15  $    0.09  $    0.27  $    0.07

Shares used in
  calculation of
  earnings per
  share (1):
 Basic                  150,477    133,524    149,167    131,937
 Diluted                167,417    156,126    167,297    156,903



(1)  Per share data for the three and six months ended June 30, 2000
     have been restated to reflect a three-for-one stock split in
     January 2001.
(2)  The financial results for the three and six months ended June 30,
     2000 have been restated to reflect the adoption of Staff
     Accounting Bulletin No. 101 as of January 1, 2000.



CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
                                          June 30,  December 31,
                                            2001       2000
                                          --------   --------
                                        (unaudited)  (audited)
Assets
Current assets:
 Cash, cash equivalents and securities
  available-for-sale                      $612,519   $581,338
 Other current assets                       64,378     49,920
                                          --------   --------
 Total current assets                      676,897    631,258

Long-term securities available-for-sale    209,030    169,188
Property and equipment, net                 57,807     47,514
Investment and other assets                  9,206      8,446
                                          --------   --------
 Total assets                             $952,940   $856,406
                                          ========   ========

Liabilities and Stockholders' Equity
Current liabilities                       $ 21,544   $ 23,045
Non-current liabilities                    142,731    138,742
Stockholders' equity                       788,665    694,619
                                          --------   --------
 Total liabilities and stockholders'
  equity                                  $952,940   $856,406
                                          ========   ========
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 19, 2001
Words:1619
Previous Article:Amazon.com to Webcast Second Quarter 2001 Financial Results Conference Call.
Next Article:Secure Computing Reports Second Quarter 2001 Operating Results.
Topics:



Related Articles
IDEC Pharmaceuticals Announces U.S. Rituxan Sales of $72.2 Million in Fourth Quarter, 1999, and $262.7 Million for the Full Year.
IDEC Pharmaceuticals Reports Second Year of Profitability On Revenue Growth of 36 Percent.
IDEC Pharmaceuticals Reports Second Quarter 2000 Results.
IDEC Pharmaceuticals Announces Net U.S. Rituxan Sales of $134.0 Million in Fourth Quarter, 2000, and $424.3 Million for the Year 2000.
Third Consecutive Year of Profitability Reported by IDEC Pharmaceuticals; Revenue Growth of 31 Percent for Year 2000.
IDEC Pharmaceuticals Reports First Quarter 2001 Results; Rituxan Sales Increase 115% Over 1Q 2000 and Earnings Increase to $0.12 Per Share.
IDEC Pharmaceuticals Announces Net U.S. Rituxan Sales of $180.0 Million in Second Quarter, 2001.
IDEC Pharmaceuticals Reports Third Quarter 2001 Results; U.S. Rituxan Sales Increase 77% Over 3Q 2000 and Earnings Increase to $0.16 Per Share.
Fourth Consecutive Year of Profitability Reported by IDEC Pharmaceuticals; Revenue Growth of 76 Percent for Year 2001.
IDEC Pharmaceuticals Reports First Quarter 2002 Results; Rituxan Sales Increase 40% Over 1Q 2001 and Earnings Increase to $0.17 Per Share On a...

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters